Sep 20, 2019 09:40 JST
Source: Eisai
|
|
|
Eisai's Promotion and Distribution Agreement with Mylan India for Eribulin Second Brand in India
Aiming to Expand Availability of Eribulin to Patients in India with Two Brands Halaven and Teceris
TOKYO, Sep 20, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that Eisai's subsidiary Eisai Pharmaceuticals India Pvt. Ltd. and Mylan N. V. subsidiary Mylan India have entered into a license agreement to promote and distribute the second brand TECERIS for the anticancer agent eribulin mesylate (eribulin) in India.
Under this agreement, eribulin will be supplied to Mylan India by Eisai India as well as promoted and distributed by Mylan India as TECERIS. Mylan India has a wide portfolio of medicines in oncology and brand building ability in India. Eisai group positions this agreement as an important strategy for expanding access to eribulin following the tiered-pricing model(*) in which the cost burden to patients is differentiated according to income level. Further availability of eribulin to patients all over India is expected by supplying eribulin in two brands, two channels: Halaven by Eisai india and TECERIS by Mylan india.
Eribulin is a novel anticancer agent discovered in-house by Eisai. In India, Eisai is steadily expanding the availability of eribulin to patients since Eisai India has launched eribulin as Halaven and introduced a tiered- pricing model in October 2013. Eribulin's indication for breast cancer in India is the locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.
The number of women diagnosed with breast cancer in India has increased in recent years, with an estimated 163,000 new cases of breast cancer and approximately 87,000 related deaths in 2018.1 Breast cancer is now the most frequently diagnosed cancer in Indian women.(1)
Eisai group positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. In addition, Eisai group will continue to adopt proactive measures aimed at increasing access to its innovative pharmaceutical products in emerging countries and the developing world in order to contribute to an increase in the benefits provided to local patients and their families.
(*) Tiered-Pricing sets the multiple cost burden to patients from full payment by the patient to free of charge in accordance with their income levels. In India, approximate 30% of patients, who have treated with Halaven, used the support program by Tiered-Pricing, and it is assumed that the patients' access to eribulin was improved by approximate 45% with the program.
About eribulin mesylate (product name: Halaven, "eribulin")
Eribulin is in the halicondrin class of microtubule dynamics inhibitors with a novel mechanism of action. Structurally, eribulin is a simplified and synthetically produced version of halichondrin B, a natural product isolated from the marine sponge halichondria okadai. Eribulin is believed to work by inhibiting the growth phase of microtubule dynamics which prevents cell division. In addition, non-clinical studies showed eribulin's unique actions in the tumor microenvironment such as an increase in vascular perfusion and permeability in tumor cores,(2) promotion of the epithelial state, decrease in capacity of breast cancer cells to migrate,(3) and etc.
Eribulin was first approved as a treatment in the United States in November 2010 for patients with metastatic breast cancer. Eribulin is currently approved for use in the treatment of breast cancer in over 70 countries worldwide, including Japan and countries in Europe, the Americas and Asia. Furthermore, eribulin was first approved as a treatment for soft tissue sarcoma in the United States in January 2016, and is approved in over 60 countries including Japan and in Europe and Asia. Furthermore, eribulin has been designated as an orphan drug for soft tissue sarcoma in the United States and Japan.
Specifically, eribulin is approved for the following indications in India.
Locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.
Unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.
About Mylan
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which more than 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at Mylan.com.
(1) International Agency for Research on Cancer (http://globocan.iarc.fr/)
(2) Funahashi Y et al., Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in
preclinical human breast cancer models. Cancer Sci., 2014; 105, 1334-1342
(3) Yoshida T et al., Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype
from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer, 2014; 110, 1497-1505
Contact:Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network. |
Latest Release
FIG, Fujitsu, Acer Medical collaborate to develop health-promoting insurance concept to support preventative care in aging societies
Oct 24, 2025 16:52 JST
| 
SHARP unveils the new "LDK+" EV concept model at Japan Mobility Show 2025
Oct 24, 2025 16:18 JST
| 
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony in Shimonoseki for Training Ship WAKASHIO MARU Built for National Institute of Technology, Toyama College
Oct 24, 2025 00:29 JST
| 
Mazda and Nippon Steel Strengthen Collaboration
Oct 23, 2025 23:57 JST
| 
Immersive Museum "THE MOVEUM YOKOHAMA by TOYOTA GROUP" to Open on December 20, 2025
Oct 23, 2025 23:27 JST
|
PacificLight Appoints a Consortium of Mitsubishi Power and Jurong Engineering Limited to build 670 MW CCGT Power Plant in Singapore
Oct 23, 2025 23:12 JST
| 
NEC and the Cote d'Ivoire Ministry of Agriculture enhance agricultural efficiency through digital technology
Oct 22, 2025 20:55 JST
|
Fujitsu and Kawasaki Frontale sign global Sports for Nature Framework in Japan first
Oct 22, 2025 18:16 JST
| 
Olympus Launches New Surgical Energy Device for Hemostatic Cutting and Vessel Sealing
Oct 21, 2025 23:00 JST
|
MHI Thermal Systems to Launch New 2026 Models of the S Series High-Capacity Residential-Use Air-Conditioners for the Japanese Market
Oct 21, 2025 22:10 JST
|
New Land Cruiser "FJ" Makes World Premiere
Oct 21, 2025 21:29 JST
|
Sharp Initiates Collaboration with ARAV Corporation for Remote Control Solutions of Construction Machinery Utilizing Satellite Communication
Oct 21, 2025 21:00 JST
| 
Hitachi and OpenAI form strategic partnership centered on global AI data center expansion
Oct 21, 2025 20:06 JST
| 
Indonesia's Legacy in the Global Vaccine Landscape: Bio Farma and DCVMN Strengthen Health Resilience through Global Partnership
Oct 21, 2025 16:45 JST
|
Olympus: "Feasibility study on the development of Japanese digitalized endoscopy infection control systems in India" Selected for METI's FY2024 Supplementary "Global South Future-Oriented Co-Creation Subsidy Program (Small-Scale Demonstration / Feasibility Study Project)"
Oct 21, 2025 11:00 JST
|
MHI Thermal Systems Air-Conditioners for the Australian Market Recognized with Prestigious Awards
Oct 17, 2025 23:37 JST
|
SEKISUI CHEMICAL, Fujitsu, and SAP Japan announce comprehensive modernization of management platform to drive data-driven approach
Oct 17, 2025 23:00 JST
| 
TransNusa to Launch Bali - Singapore Scheduled Flight on November 17
Oct 17, 2025 16:58 JST
|
MHIEC Receives Contract for Improvement of Core Equipment at Municipal Solid Waste Incineration Facility in Kanazawa
Oct 16, 2025 23:57 JST
| 
Overview of Honda Exhibits at Japan Mobility Show 2025
Oct 16, 2025 23:20 JST
|
More Latest Release >>
|